Fluxion Bio Lands NIH Grant for Antimicrobial Microfluidic Systems | GenomeWeb
NEW YORK (GenomeWeb News) – Microfluidic systems developer Fluxion Biosciences has received a Phase I grant from the National Institutes of Health to develop a platform for use in antimicrobial drug discovery and development programs, the company said today.
 
The San Francisco-based company did not disclose the amount of the grant and was not immediately available for comment.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.